BNP Paribas Financial Markets Has $12.25 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

BNP Paribas Financial Markets reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 38.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,192 shares of the biotechnology company's stock after selling 21,416 shares during the period. BNP Paribas Financial Markets owned approximately 0.08% of United Therapeutics worth $12,253,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brooklyn Investment Group bought a new stake in United Therapeutics in the third quarter valued at about $33,000. FMR LLC increased its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of United Therapeutics by 22.3% in the 3rd quarter. Fisher Asset Management LLC now owns 6,305 shares of the biotechnology company's stock valued at $2,259,000 after acquiring an additional 1,150 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of United Therapeutics by 26.1% in the 3rd quarter. Daiwa Securities Group Inc. now owns 4,119 shares of the biotechnology company's stock valued at $1,476,000 after acquiring an additional 852 shares during the period. Finally, Cerity Partners LLC grew its holdings in United Therapeutics by 82.1% during the third quarter. Cerity Partners LLC now owns 8,886 shares of the biotechnology company's stock valued at $3,184,000 after purchasing an additional 4,005 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

NASDAQ UTHR traded down $0.37 on Monday, hitting $370.12. 315,269 shares of the stock were exchanged, compared to its average volume of 456,084. The business's fifty day moving average is $367.77 and its 200 day moving average is $336.09. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market capitalization of $16.53 billion, a PE ratio of 16.27, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue was up 22.9% on a year-over-year basis. During the same period last year, the business posted $5.38 EPS. Analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Activity

In other news, COO Michael Benkowitz sold 15,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $1,034,510.88. This trade represents a 85.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock valued at $47,398,820 over the last three months. Insiders own 11.90% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Wells Fargo & Company increased their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a report on Tuesday, August 20th. Finally, Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.